CIRM Funded Clinical Trials

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation


Edward Kavalerchik
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$6,192,579
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
24
ClinicalTrials.gov ID:
Details: 

Angiocrine Bioscience Inc. will use genetically engineered cells, derived from cord blood, to see if they can help alleviate or accelerate recovery from the toxic side effects of chemotherapy for people undergoing treatment for lymphoma and other aggressive cancers of the blood or lymph system.

Design: 

First in human, Phase 1, multi-center trial

Goal: 

Safety